United Kingdom | VP, Business Operations, Takeda
Kerry Hawitt is a senior biopharmaceutical executive with leadership in technical, quality and operational roles within global organizations such as Shire, Eli Lilly and Mallinckrodt, based in Harvard, Massachusetts, USA. Kerry is a strategic business leader dedicated to improving performance and achieving compliance excellence in high change and highly regulated environments. She has a successful record of building new departments and devising and executing global transformation projects aimed at streamlining and improving business performance as evidenced by increasing compliance, productivity, cost savings and efficiencies. Kerry has expertise in GxP regulations, quality, compliance, development, manufacturing and supply for a wide range of dosage forms, such as plasma, biologics, small molecules, medical device and combination products, including device software applications. Kerry serves as an influential change agent, taking operations and engagement to the next level. She is adept at devising new processes and systems to harness data and establish KPIs to drive informed decision-making, compliance and performance improvements across global, international and local clinical and commercial product portfolios. Kerry has achieved significant operational cost reductions and team productivity gains, cultivated employee engagement and improved compliance capability across a broad range of systems, locations and products.
Kerry holds a PhD and Bachelor of Science Honors from the University of Manchester in the United Kingdom. In 2008, Kerry co-authored and co-edited “Microbiological Control in Non-Sterile Pharmaceuticals Monograph,” in conjunction with CQI, PQG and Pharmig. Kerry serves on the Board of Directors for The Discovery Museum, where she is currently working with the CEO on a special employee development project. She has also served on the strategy committee.